Provisional ethics approval for human study

SkinBioTherapeutics plc

SkinBioTherapeutics receives provisional ethics approval for human study

Manchester, UK - 18 July 2018 - SkinBioTherapeutics plc (AIM: SBTX,  the "Company"), a life sciences company focused on skin health, announces that it has received provisional ethics approval for its human study scheduled to start later this year.  

Full approval will be granted on completion of procedural amendments to the study paperwork which are underway.

The human study, scheduled for September 2018, will be conducted on 120 female volunteers with self-assessed 'dry skin' over a six week period. The study is designed to test whether the positive impact of the SkinBiotix® technology on the skin's barrier function, which has been demonstrated in laboratory studies, is replicated with human volunteers.  Measurements will be taken to assess skin dryness, skin hydration and the skin barrier function.

Dr Catherine O'Neill, CEO of SkinBioTherapeutics, commented:

"Ethics approval is a prerequisite for human clinical trials and therefore required before our human study can commence. The procedural amendments we need to make to the paperwork are straightforward and consequently we remain on track to commence the human study in September."

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 and has been arranged for release by Doug Quinn, CFO of the Company. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

-Ends-

For more information, please contact:

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain.

SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin.  The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models.  Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. 

SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix®. The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix (AIM: OPTI).

The Company joined AIM in April 2017 concurrent with raising £4.5 million from a placing of new ordinary shares.

The Company is based in Manchester, UK. For more information, visit www.skinbiotherapeutics.com.